Chernesky M, Jang D, Sellors J, Castriciano S, Pickard L, Luinstra K, Mahony J
Department of Pediatrics, St. Joseph's Hospital, Hamilton Ontario, Canada.
Sex Transm Dis. 1993 Nov-Dec;20(6):301-6.
Chlamydia trachomatis antigen testing of clinical specimens is replacing culture as the test of choice. Because of a potential for false positive results in low prevalence populations, there is an apparent need for confirming specimens positive by enzyme immunoassay (EIA).
To examine specimens falsely positive in the Chlamydiazyme EIA assay according to gender and specimen type.
Testing of genitourinary specimens from men and women consecutively enrolled from five health care delivery sources in an urban Canadian population. All specimens were initially tested in the Chlamydiazyme test and all positives repeated in a confirmatory blocking assay provided by the manufacturer. Additional confirmatory testing was performed using immunofluorescence (IF) staining for C. trachomatis elementary bodies (EB's) and polymerase chain reaction (PCR).
From Jan. 1, 1990 to June 1, 1991, multiple specimens from 656 men and 5,628 women of varying population prevalences were screened. EIA-positive specimens from women had a repeat negative rate of 22% to 27% from cervical swabs and 29% from urethral swabs. Male urethral swabs had a high repeat negative rate of 22% when EIA was the only positive test, but 2.4% when the specimen was positive by EIA and culture. EIA-positive first void urine (FVU) specimens from men had a repeat negative rate of 8.7% as opposed to 17% to 32% from women. Only 1.7% (2/115) of male FVU did not block compared to rates of 47% (22/47) to 80% (4/5) in FVU from women. Analysis of EIA optical densities (OD's) and EB counts showed an association between the absorbance range 0.1 to 1.4 OD and 0-85 EB's. The greatest number of EB's and highest OD's were seen with cervical specimens, followed by urine and urethral specimens in women infected at all three specimens. All 55 specimens that did not confirm in the blocking test had no EB's and a convenience sample of seven were negative by PCR. All of a subset of 50 blocked specimens contained EB's or were positive by PCR.
Although a variable proportion of specimens may not repeat positive in the EIA, use of the blocking reagent to confirm the repeat positives is highly recommended and the rate of blocking may be heavily influenced by gender and specimen type.
对临床标本进行沙眼衣原体抗原检测正在取代培养法成为首选检测方法。由于在低流行率人群中可能出现假阳性结果,显然需要对酶免疫测定(EIA)呈阳性的标本进行确认。
根据性别和标本类型检查在衣原体酶联免疫吸附测定(Chlamydiazyme EIA)中出现假阳性的标本。
对来自加拿大城市地区五个医疗保健机构的连续招募的男性和女性泌尿生殖系统标本进行检测。所有标本首先用衣原体酶联免疫吸附测定法进行检测,所有阳性标本再用制造商提供的确认性阻断试验进行重复检测。另外,使用针对沙眼衣原体原体(EB)的免疫荧光(IF)染色和聚合酶链反应(PCR)进行额外的确认性检测。
从1990年1月1日至1991年6月1日,对656名男性和5628名女性的不同流行率的多个标本进行了筛查。女性EIA阳性标本中,宫颈拭子的重复阴性率为22%至27%,尿道拭子为29%。男性尿道拭子在EIA是唯一阳性检测时重复阴性率较高,为22%,但当标本EIA和培养均为阳性时为2.4%。男性首次晨尿(FVU)EIA阳性标本的重复阴性率为8.7%,而女性为17%至32%。男性FVU中只有1.7%(2/115)未被阻断,而女性FVU的未被阻断率为47%(22/47)至80%(4/5)。对EIA光密度(OD)和EB计数的分析显示,吸光度范围在0.1至1.4 OD与0 - 85个EB之间存在关联。在所有三种标本均感染的女性中,宫颈标本中EB数量最多且OD最高,其次是尿液和尿道标本。在阻断试验中未得到确认的所有55个标本均未检测到EB,随机抽取的7个样本经PCR检测为阴性。50个被阻断的标本子集中,所有标本均含有EB或经PCR检测为阳性。
尽管EIA中可能有不同比例的标本不会重复呈阳性,但强烈建议使用阻断试剂来确认重复阳性结果,且阻断率可能受性别和标本类型的严重影响。